Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 66 entries
Sorted by: Best Match Show Resources per page
Placental microRNA expression associates with birthweight through control of adipokines: results from two independent cohorts.

Epigenetics

Kennedy EM, Hermetz K, Burt A, Everson TM, Deyssenroth M, Hao K, Chen J, Karagas MR, Pei D, Koestler DC, Marsit CJ.
PMID: 33016211
Epigenetics. 2021 Jun-Jul;16(7):770-782. doi: 10.1080/15592294.2020.1827704. Epub 2020 Oct 04.

MicroRNAs are non-coding RNAs that regulate gene expression post-transcriptionally. In the placenta, the master regulator of foetal growth and development, microRNAs shape the basic processes of trophoblast biology and specific microRNA have been associated with foetal growth. To comprehensively...

Cite
Kennedy EM, Hermetz K, Burt A, et al. Placental microRNA expression associates with birthweight through control of adipokines: results from two independent cohorts. Epigenetics. 2020;16(7):770-782doi: 10.1080/15592294.2020.1827704.
Kennedy, E. M., Hermetz, K., Burt, A., Everson, T. M., Deyssenroth, M., Hao, K., Chen, J., Karagas, M. R., Pei, D., Koestler, D. C., & Marsit, C. J. (2021). Placental microRNA expression associates with birthweight through control of adipokines: results from two independent cohorts. Epigenetics, 16(7), 770-782. https://doi.org/10.1080/15592294.2020.1827704
Kennedy, Elizabeth M, et al. "Placental microRNA expression associates with birthweight through control of adipokines: results from two independent cohorts." Epigenetics vol. 16,7 (2021): 770-782. doi: https://doi.org/10.1080/15592294.2020.1827704
Kennedy EM, Hermetz K, Burt A, Everson TM, Deyssenroth M, Hao K, Chen J, Karagas MR, Pei D, Koestler DC, Marsit CJ. Placental microRNA expression associates with birthweight through control of adipokines: results from two independent cohorts. Epigenetics. 2021 Jun-Jul;16(7):770-782. doi: 10.1080/15592294.2020.1827704. Epub 2020 Oct 04. PMID: 33016211; PMCID: PMC8216179.
Copy Download .nbib Format: NLM
Response to "Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression".

Kidney international reports

Yu ASL, El Ters M, Stubbs JR.
PMID: 34013132
Kidney Int Rep. 2021 Mar 27;6(5):1482-1483. doi: 10.1016/j.ekir.2021.03.878. eCollection 2021 May.

No abstract available.

Cite
Yu ASL, El Ters M, Stubbs JR. Response to "Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression". Kidney Int Rep. 2021;6(5):1482-1483doi: 10.1016/j.ekir.2021.03.878.
Yu, A. S. L., El Ters, M., & Stubbs, J. R. (2021). Response to "Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression". Kidney international reports, 6(5), 1482-1483. https://doi.org/10.1016/j.ekir.2021.03.878
Yu, Alan S L, et al. "Response to "Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression"." Kidney international reports vol. 6,5 (2021): 1482-1483. doi: https://doi.org/10.1016/j.ekir.2021.03.878
Yu ASL, El Ters M, Stubbs JR. Response to "Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression". Kidney Int Rep. 2021 Mar 27;6(5):1482-1483. doi: 10.1016/j.ekir.2021.03.878. eCollection 2021 May. PMID: 34013132; PMCID: PMC8116772.
Copy Download .nbib Format: NLM
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

Nature communications

Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teulé A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC.
PMID: 33990587
Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4.

A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-23162-4.

Cite
Coignard J, Lush M, Beesley J, et al. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021;12(1):2986doi: 10.1038/s41467-021-23162-4.
Coignard, J., Lush, M., Beesley, J., O'Mara, T. A., Dennis, J., Tyrer, J. P., Barnes, D. R., McGuffog, L., Leslie, G., Bolla, M. K., Adank, M. A., Agata, S., Ahearn, T., Aittomäki, K., Andrulis, I. L., Anton-Culver, H., Arndt, V., Arnold, N., Aronson, K. J., Arun, B. K., Augustinsson, A., Azzollini, J., Barrowdale, D., Baynes, C., Becher, H., Bermisheva, M., Bernstein, L., Białkowska, K., Blomqvist, C., Bojesen, S. E., Bonanni, B., Borg, A., Brauch, H., Brenner, H., Burwinkel, B., Buys, S. S., Caldés, T., Caligo, M. A., Campa, D., Carter, B. D., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Chung, W. K., Claes, K. B. M., Clarke, C. L., Collée, J. M., Conroy, D. M., Czene, K., Daly, M. B., Devilee, P., Diez, O., Ding, Y. C., Domchek, S. M., Dörk, T., Dos-Santos-Silva, I., Dunning, A. M., Dwek, M., Eccles, D. M., Eliassen, A. H., Engel, C., Eriksson, M., Evans, D. G., Fasching, P. A., Flyger, H., Fostira, F., Friedman, E., Fritschi, L., Frost, D., Gago-Dominguez, M., Gapstur, S. M., Garber, J., Garcia-Barberan, V., García-Closas, M., García-Sáenz, J. A., Gaudet, M. M., Gayther, S. A., Gehrig, A., Georgoulias, V., Giles, G. G., Godwin, A. K., Goldberg, M. S., Goldgar, D. E., González-Neira, A., Greene, M. H., Guénel, P., Haeberle, L., Hahnen, E., Haiman, C. A., Håkansson, N., Hall, P., Hamann, U., Harrington, P. A., Hart, S. N., He, W., Hogervorst, F. B. L., Hollestelle, A., Hopper, J. L., Horcasitas, D. J., Hulick, P. J., Hunter, D. J., Imyanitov, E. N., Jager, A., Jakubowska, A., James, P. A., Jensen, U. B., John, E. M., Jones, M. E., Kaaks, R., Kapoor, P. M., Karlan, B. Y., Keeman, R., Khusnutdinova, E., Kiiski, J. I., Ko, Y. D., Kosma, V. M., Kraft, P., Kurian, A. W., Laitman, Y., Lambrechts, D., Le Marchand, L., Lester, J., Lesueur, F., Lindstrom, T., Lopez-Fernández, A., Loud, J. T., Luccarini, C., Mannermaa, A., Manoukian, S., Margolin, S., Martens, J. W. M., Mebirouk, N., Meindl, A., Miller, A., Milne, R. L., Montagna, M., Nathanson, K. L., Neuhausen, S. L., Nevanlinna, H., Nielsen, F. C., O'Brien, K. M., Olopade, O. I., Olson, J. E., Olsson, H., Osorio, A., Ottini, L., Park-Simon, T. W., Parsons, M. T., Pedersen, I. S., Peshkin, B., Peterlongo, P., Peto, J., Pharoah, P. D. P., Phillips, K. A., Polley, E. C., Poppe, B., Presneau, N., Pujana, M. A., Punie, K., Radice, P., Rantala, J., Rashid, M. U., Rennert, G., Rennert, H. S., Robson, M., Romero, A., Rossing, M., Saloustros, E., Sandler, D. P., Santella, R., Scheuner, M. T., Schmidt, M. K., Schmidt, G., Scott, C., Sharma, P., Soucy, P., Southey, M. C., Spinelli, J. J., Steinsnyder, Z., Stone, J., Stoppa-Lyonnet, D., Swerdlow, A., Tamimi, R. M., Tapper, W. J., Taylor, J. A., Terry, M. B., Teulé, A., Thull, D. L., Tischkowitz, M., Toland, A. E., Torres, D., Trainer, A. H., Truong, T., Tung, N., Vachon, C. M., Vega, A., Vijai, J., Wang, Q., Wappenschmidt, B., Weinberg, C. R., Weitzel, J. N., Wendt, C., Wolk, A., Yadav, S., Yang, X. R., Yannoukakos, D., Zheng, W., Ziogas, A., Zorn, K. K., Park, S. K., Thomassen, M., Offit, K., Schmutzler, R. K., Couch, F. J., Simard, J., Chenevix-Trench, G., Easton, D. F., Andrieu, N., & Antoniou, A. C. (2021). Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature communications, 12(1), 2986. https://doi.org/10.1038/s41467-021-23162-4
Coignard, Juliette, et al. "Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers." Nature communications vol. 12,1 (2021): 2986. doi: https://doi.org/10.1038/s41467-021-23162-4
Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teulé A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4. PMID: 33990587; PMCID: PMC8121813.
Copy Download .nbib Format: NLM
Isolation and analysis methods of extracellular vesicles (EVs).

Extracellular vesicles and circulating nucleic acids

Zhao Z, Wijerathne H, Godwin AK, Soper SA.
PMID: 34414401
Extracell Vesicles Circ Nucl Acids. 2021;2:80-103. doi: 10.20517/evcna.2021.07. Epub 2020 Mar 30.

Extracellular vesicles (EVs) have been recognized as an evolving biomarker within the liquid biopsy family. While carrying both host cell proteins and different types of RNAs, EVs are also present in sufficient quantities in biological samples to be tested...

Cite
Zhao Z, Wijerathne H, Godwin AK, et al. Isolation and analysis methods of extracellular vesicles (EVs). Extracell Vesicles Circ Nucl Acids. 2020;2:80-103doi: 10.20517/evcna.2021.07.
Zhao, Z., Wijerathne, H., Godwin, A. K., & Soper, S. A. (2021). Isolation and analysis methods of extracellular vesicles (EVs). Extracellular vesicles and circulating nucleic acids, 280-103. https://doi.org/10.20517/evcna.2021.07
Zhao, Zheng, et al. "Isolation and analysis methods of extracellular vesicles (EVs)." Extracellular vesicles and circulating nucleic acids vol. 2 (2021): 80-103. doi: https://doi.org/10.20517/evcna.2021.07
Zhao Z, Wijerathne H, Godwin AK, Soper SA. Isolation and analysis methods of extracellular vesicles (EVs). Extracell Vesicles Circ Nucl Acids. 2021;2:80-103. doi: 10.20517/evcna.2021.07. Epub 2020 Mar 30. PMID: 34414401; PMCID: PMC8372011.
Copy Download .nbib Format: NLM
Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk.

JNCI cancer spectrum

Michaud DS, Ruan M, Koestler DC, Pei D, Marsit CJ, De Vivo I, Kelsey KT.
PMID: 33134824
JNCI Cancer Spectr. 2020 May 19;4(5):pkaa041. doi: 10.1093/jncics/pkaa041. eCollection 2020 Oct.

BACKGROUND: Epigenome-wide association studies using peripheral blood have identified specific sites of DNA methylation associated with risk of various cancers and may hold promise to identify novel biomarkers of risk; however, few studies have been performed for pancreatic cancer...

Cite
Michaud DS, Ruan M, Koestler DC, et al. Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk. JNCI Cancer Spectr. 2020;4(5):pkaa041doi: 10.1093/jncics/pkaa041.
Michaud, D. S., Ruan, M., Koestler, D. C., Pei, D., Marsit, C. J., De Vivo, I., & Kelsey, K. T. (2020). Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk. JNCI cancer spectrum, 4(5), pkaa041. https://doi.org/10.1093/jncics/pkaa041
Michaud, Dominique S, et al. "Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk." JNCI cancer spectrum vol. 4,5 (2020): pkaa041. doi: https://doi.org/10.1093/jncics/pkaa041
Michaud DS, Ruan M, Koestler DC, Pei D, Marsit CJ, De Vivo I, Kelsey KT. Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk. JNCI Cancer Spectr. 2020 May 19;4(5):pkaa041. doi: 10.1093/jncics/pkaa041. eCollection 2020 Oct. PMID: 33134824; PMCID: PMC7583152.
Copy Download .nbib Format: NLM
Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing.

Clinical and translational science

Oni-Orisan A, Srinivas N, Mehta K, Das JL, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA.
PMID: 33421282
Clin Transl Sci. 2021 May;14(3):784-790. doi: 10.1111/cts.12973. Epub 2021 Feb 12.

Although traditional approaches to biomarker discovery have elucidated key molecular markers that have improved drug selection (precision medicine), the discovery of biomarkers that inform optimal dose selection (precision dosing) continues to be a challenge in many therapeutic areas. Larger...

Cite
Oni-Orisan A, Srinivas N, Mehta K, et al. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clin Transl Sci. 2021;14(3):784-790doi: 10.1111/cts.12973.
Oni-Orisan, A., Srinivas, N., Mehta, K., Das, J. L., Nguyen, T. T., Tison, G. H., Bauer, S. R., Burian, M., Funk, R. S., Graham, R. A. (2021). Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clinical and translational science, 14(3), 784-790. https://doi.org/10.1111/cts.12973
Oni-Orisan, Akinyemi, et al. "Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing." Clinical and translational science vol. 14,3 (2021): 784-790. doi: https://doi.org/10.1111/cts.12973
Oni-Orisan A, Srinivas N, Mehta K, Das JL, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clin Transl Sci. 2021 May;14(3):784-790. doi: 10.1111/cts.12973. Epub 2021 Feb 12. PMID: 33421282; PMCID: PMC8212753.
Copy Download .nbib Format: NLM
Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease.

Pharmaceuticals (Basel, Switzerland)

Morrow R, Funk R, Becker M, Sherman A, Van Haandel L, Hudson T, Casini R, Shakhnovich V.
PMID: 34069031
Pharmaceuticals (Basel). 2021 May 14;14(5). doi: 10.3390/ph14050463.

Inside cells, the immunomodulator methotrexate (MTX) undergoes the addition of glutamates to form methotrexate polyglutamates (MTX-Glu)-promising biomarkers of systemic exposure and treatment response to MTX in rheumatology. MTX-Glu are underexplored in Inflammatory Bowel Disease (IBD), with no data in...

Cite
Morrow R, Funk R, Becker M, et al. Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease. Pharmaceuticals (Basel). 2021;14(5)doi: 10.3390/ph14050463.
Morrow, R., Funk, R., Becker, M., Sherman, A., Van Haandel, L., Hudson, T., Casini, R., & Shakhnovich, V. (2021). Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease. Pharmaceuticals (Basel, Switzerland), 14(5), . https://doi.org/10.3390/ph14050463
Morrow, Ryan, et al. "Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease." Pharmaceuticals (Basel, Switzerland) vol. 14,5 (2021). doi: https://doi.org/10.3390/ph14050463
Morrow R, Funk R, Becker M, Sherman A, Van Haandel L, Hudson T, Casini R, Shakhnovich V. Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease. Pharmaceuticals (Basel). 2021 May 14;14(5). doi: 10.3390/ph14050463. PMID: 34069031; PMCID: PMC8156207.
Copy Download .nbib Format: NLM
Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood.

Epigenetics

Zhao N, Ruan M, Koestler DC, Lu J, Marsit CJ, Kelsey KT, Platz EA, Michaud DS.
PMID: 34008478
Epigenetics. 2021 May 19;1-13. doi: 10.1080/15592294.2021.1923615. Epub 2021 May 19.

BACKGROUND: DNA methylation markers have been associated with lung cancer risk and may identify aetiologically relevant genomic regions, or alternatively, be markers of disease risk factors or biological processes associated with disease development.METHODS: In a nested case-control study, we...

Cite
Zhao N, Ruan M, Koestler DC, et al. Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood. Epigenetics. 2021;1-13doi: 10.1080/15592294.2021.1923615.
Zhao, N., Ruan, M., Koestler, D. C., Lu, J., Marsit, C. J., Kelsey, K. T., Platz, E. A., & Michaud, D. S. (2021). Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood. Epigenetics, 1-13. https://doi.org/10.1080/15592294.2021.1923615
Zhao, Naisi, et al. "Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood." Epigenetics vol. (2021): 1-13. doi: https://doi.org/10.1080/15592294.2021.1923615
Zhao N, Ruan M, Koestler DC, Lu J, Marsit CJ, Kelsey KT, Platz EA, Michaud DS. Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood. Epigenetics. 2021 May 19;1-13. doi: 10.1080/15592294.2021.1923615. Epub 2021 May 19. PMID: 34008478.
Copy Download .nbib Format: NLM
DNA methylation ageing clocks and pancreatic cancer risk: pooled analysis of three prospective nested case-control studies.

Epigenetics

Chung M, Ruan M, Zhao N, Koestler DC, De Vivo I, Kelsey KT, Michaud DS.
PMID: 33315530
Epigenetics. 2021 Dec;16(12):1306-1316. doi: 10.1080/15592294.2020.1861401. Epub 2021 Jan 07.

DNA methylation (DNAm) age may reflect age-related variations in biological changes and abnormalities related to ageing. DNAm age acceleration measures have been associated with a number of cancers, but to our knowledge, have not been examined in relation to...

Cite
Chung M, Ruan M, Zhao N, et al. DNA methylation ageing clocks and pancreatic cancer risk: pooled analysis of three prospective nested case-control studies. Epigenetics. 2021;16(12):1306-1316doi: 10.1080/15592294.2020.1861401.
Chung, M., Ruan, M., Zhao, N., Koestler, D. C., De Vivo, I., Kelsey, K. T., & Michaud, D. S. (2021). DNA methylation ageing clocks and pancreatic cancer risk: pooled analysis of three prospective nested case-control studies. Epigenetics, 16(12), 1306-1316. https://doi.org/10.1080/15592294.2020.1861401
Chung, Mei, et al. "DNA methylation ageing clocks and pancreatic cancer risk: pooled analysis of three prospective nested case-control studies." Epigenetics vol. 16,12 (2021): 1306-1316. doi: https://doi.org/10.1080/15592294.2020.1861401
Chung M, Ruan M, Zhao N, Koestler DC, De Vivo I, Kelsey KT, Michaud DS. DNA methylation ageing clocks and pancreatic cancer risk: pooled analysis of three prospective nested case-control studies. Epigenetics. 2021 Dec;16(12):1306-1316. doi: 10.1080/15592294.2020.1861401. Epub 2021 Jan 07. PMID: 33315530.
Copy Download .nbib Format: NLM
Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle.

Function (Oxford, England)

Morris JK, McCoin CS, Fuller KN, John CS, Wilkins HM, Green ZD, Wang X, Sharma P, Burns JM, Vidoni ED, Mahnken JD, Shankar K, Swerdlow RH, Thyfault JP.
PMID: 34661111
Function (Oxf). 2021 Sep 02;2(6):zqab045. doi: 10.1093/function/zqab045. eCollection 2021.

Alzheimer's Disease (ad) associates with insulin resistance and low aerobic capacity, suggestive of impaired skeletal muscle mitochondrial function. However, this has not been directly measured in AD. This study (

Cite
Morris JK, McCoin CS, Fuller KN, et al. Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle. Function (Oxf). 2021;2(6):zqab045doi: 10.1093/function/zqab045.
Morris, J. K., McCoin, C. S., Fuller, K. N., John, C. S., Wilkins, H. M., Green, Z. D., Wang, X., Sharma, P., Burns, J. M., Vidoni, E. D., Mahnken, J. D., Shankar, K., Swerdlow, R. H., & Thyfault, J. P. (2021). Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle. Function (Oxford, England), 2(6), zqab045. https://doi.org/10.1093/function/zqab045
Morris, Jill K, et al. "Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle." Function (Oxford, England) vol. 2,6 (2021): zqab045. doi: https://doi.org/10.1093/function/zqab045
Morris JK, McCoin CS, Fuller KN, John CS, Wilkins HM, Green ZD, Wang X, Sharma P, Burns JM, Vidoni ED, Mahnken JD, Shankar K, Swerdlow RH, Thyfault JP. Mild Cognitive Impairment and Donepezil Impact Mitochondrial Respiratory Capacity in Skeletal Muscle. Function (Oxf). 2021 Sep 02;2(6):zqab045. doi: 10.1093/function/zqab045. eCollection 2021. PMID: 34661111; PMCID: PMC8515006.
Copy Download .nbib Format: NLM
Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.

JAMA oncology

Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J.
PMID: 33885704
JAMA Oncol. 2021 Jun 01;7(6):845-852. doi: 10.1001/jamaoncol.2021.0687.

IMPORTANCE: Stereotactic body radiotherapy (SBRT) for oligometastases is hypothesized to improve survival and is increasingly used. Little evidence supports its safe use to treat patients with multiple metastases.OBJECTIVE: To establish safety of SBRT dose schedules in patients with 3...

Cite
Chmura S, Winter KA, Robinson C, et al. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021;7(6):845-852doi: 10.1001/jamaoncol.2021.0687.
Chmura, S., Winter, K. A., Robinson, C., Pisansky, T. M., Borges, V., Al-Hallaq, H., Matuszak, M., Park, S. S., Yi, S., Hasan, Y., Bazan, J., Wong, P., Yoon, H. A., Horton, J., Gan, G., Milano, M. T., Sigurdson, E. R., Moughan, J., Salama, J. K., & White, J. (2021). Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA oncology, 7(6), 845-852. https://doi.org/10.1001/jamaoncol.2021.0687
Chmura, Steve, et al. "Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial." JAMA oncology vol. 7,6 (2021): 845-852. doi: https://doi.org/10.1001/jamaoncol.2021.0687
Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Jun 01;7(6):845-852. doi: 10.1001/jamaoncol.2021.0687. PMID: 33885704; PMCID: PMC8063134.
Copy Download .nbib Format: NLM
Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States.

JAMA network open

Shete S, Deng Y, Shannon J, Faseru B, Middleton D, Iachan R, Bernardo B, Balkrishnan R, Kim SJ, Huang B, Millar MM, Fuemmler B, Jensen JD, Mendoza JA, Hu J, Lazovich D, Robertson L, Demark-Wahnefried W, Paskett ED.
PMID: 34605915
JAMA Netw Open. 2021 Oct 01;4(10):e2128000. doi: 10.1001/jamanetworkopen.2021.28000.

IMPORTANCE: Screening for breast and colorectal cancer has resulted in reductions in mortality; however, questions remain regarding how these interventions are being diffused to all segments of the population. If an intervention is less amenable to diffusion, it could...

Cite
Shete S, Deng Y, Shannon J, et al. Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA Netw Open. 2021;4(10):e2128000doi: 10.1001/jamanetworkopen.2021.28000.
Shete, S., Deng, Y., Shannon, J., Faseru, B., Middleton, D., Iachan, R., Bernardo, B., Balkrishnan, R., Kim, S. J., Huang, B., Millar, M. M., Fuemmler, B., Jensen, J. D., Mendoza, J. A., Hu, J., Lazovich, D., Robertson, L., Demark-Wahnefried, W., Paskett, E. D. (2021). Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA network open, 4(10), e2128000. https://doi.org/10.1001/jamanetworkopen.2021.28000
Shete, Sanjay, et al. "Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States." JAMA network open vol. 4,10 (2021): e2128000. doi: https://doi.org/10.1001/jamanetworkopen.2021.28000
Shete S, Deng Y, Shannon J, Faseru B, Middleton D, Iachan R, Bernardo B, Balkrishnan R, Kim SJ, Huang B, Millar MM, Fuemmler B, Jensen JD, Mendoza JA, Hu J, Lazovich D, Robertson L, Demark-Wahnefried W, Paskett ED. Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA Netw Open. 2021 Oct 01;4(10):e2128000. doi: 10.1001/jamanetworkopen.2021.28000. PMID: 34605915; PMCID: PMC8491105.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 66 entries